Primary outcome from the ASPIRED trial presented at DDW
Now in Science
COVID Symptom Tracker
The COPE Consortium - A Call to Action During the COVID-19 Crisis
Join the COPE Consortium
Learn more about our microbiome studies

WELCOME TO THE DREW LAB

Learn more about the research being performed by Dr. David A. Drew, his lab, and the MGH Clinical & Translational Epidemiology Unit Biobank

 

RESEARCH

Specific Areas of Interest

Our lab focuses on translating epidemiological and clinical observations into biological mechanisms for disease that may be leveraged for precision medicine biomarker development.

Blood Sample

CTEU BIOBANK / EPICORE

It is the mission of the CTEU Biobank to assist researchers within the CTEU performing clinical trials to provide clinical research coordination, wide-ranging biorepository support, and downstream biological specimen handling and preparation to rapidly advance proposed analyses. Out of this effort, we launched the EPICORE service for investigators within the MGH Department of Medicine. For more information visit the EPICORE website.

C-19%20Logo_edited.jpg

COVID SYMPTOM TRACKER

Through a unique industry-academia collaboration, we have launched the COVID Symptom Tracker smartphone app in the US, UK and Sweden to better understand the global COVID-19 pandemic. This real-time epidemiology tool allows us to identify hotspots according to symptom reporting by users.

Image by Hal Gatewood

ASPIRIN CHEMOPREVENTION

We have developed several translational approaches and a robust biobank of patient-derived biopsecimens from individuals at risk for colorectal cancer as a part of the ASPIRED randomized, placebo-controlled trial.

Microbiome_edited.png

THE GUT MICROBIOME

Our lab aims to understand microbial determinants of human health using whole-shotgun meta'omics (metagenomes, metatranscriptomes, and metabolomes) derived from human fecal samples. Specific projects aim to understand microbially-mediated mechanisms of chemoprevention or immunotherapy-related adverse events.

1200px-Stand_up_to_Cancer_logo.png

EARLY DETECTION AND INTERCEPTION OF CANCER

Our lab and biobank aims to develop novel tools, approaches, and clinical paradigms to improve early detection and interception of cancer and precancers through the development of molecular-based imaging agents and circulating/stool based biomarkers. This effort is strongly supported by two Stand Up To Cancer grants.

Groceries

UNDERSTANDING PERSONALIZED RESPONSES TO FOOD

Our lab is now a part of two of the largest efforts to ever attempt to understand individual metabolic responses to food through the PREDICT family of studies and as the New England Clinical Center as a part of the NIH Common Fund's Nutrition for Precision Health, Powered by the All of Us Research Program

 
 

LATEST HAPPENINGS

Follow The Drew Lab on Twitter